Hospital

Tenofovir alafenamide (Vemlidy; Gilead Science) approved for the treatment of chronic hepatitis B virus infection in pediatric patients aged 12 years and older with compensated liver disease.

Results suggest pharmacists should use the phrase “bad reaction” to avoid stigma associated with the term “overdose.”

Three key opportunities for oncology stewardship are dose rounding, implementation of biosimilars, and management of sites of care.

Implementing screening tools, conducting brief interventions, and involving pharmacists can help manage alcohol use disorder and Alcohol Withdrawal Syndrome.

Scott Soefje, director of Pharmacy Cancer Care and assistant professor of Pharmacy at Mayo Clinic, discusses the role of PD-1 inhibitors in treating non–small cell lung cancer.

Diversity, equity, and inclusion programs in pharmacy can lead to better health outcomes for patients.

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

The findings could also help explain why certain comorbidities persist following other viral infections, including COVID-19.

Data show that despite declines in visit rates to federally qualified health centers, patients with psychological disorder diagnoses during COVID-19 did well when telemedicine was available.

Nearly 8 out of 10 individuals within the recommended age range for colorectal cancer screening are considered to have an average risk for the disease.

Program provides a virtual assessment and treatment with buprenorphine, a medication for opioid cravings and withdrawal symptoms.

Olutasidenib (Rezlidhia) is indicated for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation detected by an FDA-approved test.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

Patient selection is a key factor in the safe and effective administration of advanced pain management modalities.

Data suggest that few US adults are aware that wine can increase the risk of cancer.

The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis.

Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.

Investigators model 2 hypothetical cities as interconnected networks with a combined population of 100,000 bisexual, gay, and other men who have sex with men.

DeepTCR system showed efficacy as a predictive clinical tool and provided information on the biological mechanisms that underlie how patients respond to immunotherapy.

Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.

Although it has received less attention as flu season begins, public health experts are continuing to urge vaccination against monkeypox.

The 2022 theme is “Putting Ourselves to the Test: Achieving Equity to End HIV.”

Challenges for uptake of long-acting injectable pre-exposure prophylaxis in populations at risk for HIV include fear of needles, potential adverse effects, and concerns about diminished efficacy.

Pharmacy Times will be covering the American Society of Health-System Pharmacists 2022 Midyear Clinical Meeting from December 4 to 8.

An experimental drug could help scientists understand the development of mantle cell lymphoma and potentially increase overall survival.

Comedy has taught me several keys that have helped alleviate and manage burnout.

Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.

GSK3036656 demonstrates early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.

Study suggests that high levels of nicotinamide riboside could increase the risk of developing triple-negative breast cancer and may cause the cancer to metastasize to the brain.